ALBANY, N.Y., Sept. 29, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the Company has completed patient enrollment in its multi-center European prospective NanoKnife® System trial (ONC-205) for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
